TransPharma Medical Ltd. Announces Successful Completion of Phase 2 Trial of ViaDerm-hPTH (1-34) in Postmenopausal Women with Osteoporosis

Published: Sep 01, 2009

LOD, Israel--(BUSINESS WIRE)--TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

Back to news